科伦药业 (002422)

SICHUAN KELUN PHARMACEUTICAL CO., LTD.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexMSCI Component StocksMid Cap ValueCSI 100 IndexCSI 200 IndexCSI A100 IndexGeneric DrugsInnovative DrugsChemical PharmaceuticalsNorthbound Heavy PositionsGuozheng Value IndexFund Reduction PositionsFund Heavy PositionsHelicobacter PyloriPrivate Enterprises 100 IndexHigh-Performing StocksBidding TargetsNon-Cyclical StocksShenzhen Main Board 50 IndexShenzhen ConnectSZSE 100 IndexSZSE 300 IndexSZSE Value IndexSZSE Growth IndexTech 100 IndexPharma & BiotechSZSE Defensive 50 IndexStable Growth IndexSHS Technology Leaders IndexConsumer Services IndexSZSE Medicine Equal Weight IndexSME 100 Return IndexSZSE 100 Equal Weight IndexZhongchuang Equal Weight IndexShenzhen A-Share Pharmaceutical IndexBOC International CSI 300 ESG IndexCSI 100 Low Volatility IndexCSI All-share Pharmaceutical Sector IndexSHS Technology 100 IndexSZSE 1000 IndexSME Board Equal Weight IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCR Foundation IndexSME Board Value IndexZhongchuang Value IndexCSI 500 Value Stable IndexState-owned Enterprises Belt and Road IndexInfluenza/MaskNew Virus PreventionCOVID-19 PreventionConvertible Bond IssuersMSCIFTSE Russell ConceptShareholding Increase CommitmentLarge-cap Blue-chipInsurance Heavy HoldingsSME Board Responsibility IndexCSI 300 Non-cyclical IndexPension Industry IndexSME Board Composite IndexSZSE Selected IndexTechnology 50 Strategy IndexCS High-end Manufacturing IndexCSI 300 Shenzhen Market IndexZhongchuang 100 Return IndexSZSE Technology IndexCSI 300 ESG Leading IndexSZSE 100 Return IndexManufacturing IndexSHS Innovative Drugs IndexTechnology Pioneer IndexSustainable Development IndexSecurities Times Value 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexCSI 300 Preferred IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexSZSE Private Enterprises IndexHua Xia Bank ESG IndexCS Pharmaceutical Innovation IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSME Board Low Volatility IndexSZSE 300 Equal Weight IndexCSI Pharmaceutical IndexZhaoyang 100 IndexCSI 500 Equal Weight IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexInnovative Drugs 30 IndexCSI 300 Value Stable IndexCSI 300 Pharmaceutical IndexSME Board Performance IndexSME & ChiNext Q IndexHigh Dividend Yield Strategy IndexCSI 700 IndexSME Board Dividend IndexAH Economic Blue-chip IndexMid-small Cap IndexSZSE Fundamental 200 IndexCSI 500 IndexCSI 500 IndexPharmaceutical 50 IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexSZSE 200 Return IndexSZSE 200 IndexYangtze River 100 IndexMid-cap Low Volatility IndexCICC 300 IndexZhongchuang 400 IndexCS Innovative Drugs IndexESG 300 IndexChina Economic Index GDPJuchao Mid-cap IndexCSI 1000 Value IndexSZSE Fundamental 120 IndexSZSE 500 IndexFundamental 600 IndexCSI 500 ESG IndexCSI 500 Growth Valuation IndexSichuan

K-Line Chart

No K-line data available

Company NameSichuan Kelun Pharmaceutical Co., Ltd.
Listing Date2010-06-03
Issue Price83.36RMB
Registered Capital159805.337210k RMB
Legal RepresentativeLiu Gexin
Registered AddressNo. 2 South Road, Xindu Satellite City Industrial Development Zone, Chengdu, Sichuan Province
IndustryChemical Pharmaceuticals
Main BusinessDevelopment, production, and sales of large-volume infusion products
Company ProfileSichuan Kelun Pharmaceutical Co., Ltd. is a highly specialized and innovative pharmaceutical group. In 2017, Kelun ranked 155th among China's Top 500 Manufacturing Enterprises and its overall strength placed it among the top three in China's pharmaceutical industry. The self-developed Keli Bag is an industry-first both domestically and internationally, holding over twenty patents and winning the National Science and Technology Progress Award. It offers higher safety and cost-effectiveness compared to traditional infusions, along with significant application value in reducing energy consumption and environmental protection. It represents the development direction of China's infusion products and has profoundly reshaped the industry landscape.

Stock Details

1. Key Indicators

  • Total Shares(W): 159805.34
  • Circulating A-Shares(W): 130587.47
  • Earnings Per Share(RMB): 0.7500
  • Net Assets Per Share(RMB): 14.8354
  • Operating Revenue(W RMB): 1327672.98
  • Total Profit(W RMB): 164893.01
  • Net Profit Attributable to Parent(W RMB): 120066.57
  • Net Profit Growth Rate(%): -51.41
  • Weighted Return on Equity(%): 5.1800
  • Operating Cash Flow Per Share(RMB): 1.0540
  • Undistributed Profit Per Share(RMB): 7.3855
  • Capital Reserve Per Share(RMB): 5.4703

2. Main Business

The main business covers:

  • Research, production and sales of 24 dosage forms of drugs, including large-volume injections (infusions), small-volume injections, sterile powder injections (including divided powder injections and freeze-dried powder injections), tablets, capsules, granules, oral liquids, and peritoneal dialysis solutions.
  • Research, production and sales of antibiotic intermediates, active pharmaceutical ingredients (APIs), and pharmaceutical packaging materials.

3. Company Basic Information

  • Company Name: Sichuan Kelun Pharmaceutical Co., Ltd.
  • Listing Date: 2010-06-03
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 36 Baihua West Road, Qingyang District, Chengdu City, Sichuan Province
  • Website: www.kelun.com
  • Company Profile: The predecessor of the issuer, Sichuan Kelun Pharmaceutical Factory Co., Ltd., was established on May 29, 2002. On July 5, 2003, with the approval of the Sichuan Provincial People's Government, Kelun Limited was wholly transformed into a joint stock company. The company was registered and established on September 28, 2003, by the Chengdu Administration for Industry and Commerce.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Ya'an State-owned Assets Operation Co., Ltd. General Legal Person 9698.32 7.43
2 China Europe Healthcare Hybrid Securities Investment Fund A Fund 4006.24 3.07
3 Hong Kong Securities Clearing Company Ltd. Northbound Funds 3472.80 2.66
4 GF Multi-Factor Flexible Allocation Hybrid Securities Investment Fund Fund 2423.35 1.86
5 ICBC Credit Suisse Frontier Healthcare Equity Securities Investment Fund A Fund 2000.00 1.53
6 Huatai-PineBridge CSI 300 ETF Fund 1908.41 1.46
7 E Fund CSI 300 Healthcare ETF Fund 1403.83 1.08
8 Fullgoal Precision Healthcare Flexible Allocation Hybrid Securities Investment Fund A Fund 1094.75 0.84
9 Yinhua CSI Innovative Pharmaceutical Industry ETF Fund 1092.31 0.84
10 Penghua Ingenuity Selection Hybrid Securities Investment Fund A Fund 756.00 0.58

5. Concept Sectors

  • Generic Drugs
  • Helicobacter Pylori
  • Hepatitis Concept
  • Innovative Drugs
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Heavily Held by Funds
  • Subject to Takeover Bid
  • MSCI Constituent
  • Spin-off Listing
  • Funds Reducing Holdings
  • Heavily Held by Northbound Funds
  • Non-Cyclical Stocks
  • CSI 100
  • SZSE Value
  • CSI Mid-Small Cap 100
  • SME 100
  • Mid-Cap Value
  • SZSE 100
  • SZSE 300
  • SZSE Dividend
  • Consumption 100
  • Private Enterprise 100
  • SZSE National Value
  • SZSE Growth
  • CSI 300
  • SME 300
  • CSI 200
  • CSI 300 Non-Cyclical
  • SZSE Innovation
  • Innovation 100
  • CSI 300 ESG
  • SZSE 50
  • SZSE Main Board 50
  • CSI A100

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information